Insulet raises annual revenue forecast on strong demand for insulin pumps
Nov 7(Reuters) -Insulet PODD.O raised its annual revenue growth forecast on Thursday, banking on strongdemand for its wearable insulin pumps.
Shares of the medical device maker rose about 2.5% to $251 in extended trading.
The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% growth, driven by strong sales of its Omnipod devices.
Insulet produces and sells Omnipod, an automated insulin delivery device, which works without the external tubing required by conventional pumps and eliminates the need for multiple daily injections for people with insulin-dependent diabetes.
The U.S. Food and Drug Administration in late August approved the expanded use of the company's Omnipod 5 device for patients with type 2 diabetes, making it the first such system to be cleared for use in both type 1 and type 2 diabetes.
In September, the company said that it expects new customer additions to be stronger in the second half of this year compared to the same period last year.
The Acton, Massachusetts-based company's total revenue jumped 25.7% to $543.9 million for the quarter ended Sept. 30, beating analysts' estimate of $519.03 million, according to data compiled by LSEG.
The company expects Omnipod revenue growth in the range of 21% to 22% for 2024.
Sales of Omnipod insulin pumps came in at $533.6 million for the third quarter, compared with analysts' estimate of $513.83 million.
On an adjusted basis, the company earned 90 cents per share in the quarter, above analysts' average estimate of 76 cents per share.
Reporting by Sruthi Narasimha Chari in Bengaluru; Editing by Mohammed Safi Shamsi
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
